Tiotropium in asthma – perspectives for the primary care physician

References

• Global Initiative for Asthma [Internet]. Global strategy for asthma management and prevention. 2020. [ cited 2020 Apr 10]. Available from: https://ginasthma.org/gina-reports/
   Google Scholar
• Centers for Disease Control and Prevention [Internet]. Most recent national asthma data. [ cited 2019 Nov 20]. Available from: https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm.
   Google Scholar
• Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012;5:CD002314.
   PubMed Web of Science ®Google Scholar
• Dahl R, Larsen BB, Venge P. Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med. 2002;96(6):432–438.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease [Internet]. Global strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease. 2020. [ cited 2020 Feb 18]. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf.
   Google Scholar
• Cazzola M, Ora J, Rogliani P, et al. Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017;11(3):239–253.
   PubMed Web of Science ®Google Scholar
• FDA [Internet]. Spiriva® Respimat® new drug application approval by FDA. [ cited 2019 Nov 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207070Orig1s000ltr.pdf.
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc. [Internet]. SPIRIVA® RESPIMAT® [Package Insert]. [ cited 2019 Sep 10]. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva%20Respimat/spirivarespimat.pdf.
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc. [Internet]. FDA expands approval of SPIRIVA® RESPIMAT® (tiotropium bromide) inhalation spray for maintenance treatment of asthma in children. [ cited 2019 Nov 20]. Available from: https://www.boehringer-ingelheim.us/press-release/fda-expands-approval-spiriva-respimat-tiotropium-bromide-inhalation-spray.
   Google Scholar
• Datapharm [Internet]. Spiriva® Respimat® summary of product characteristics. [ cited 2019 Dec 31]. Available from: https://www.medicines.org.uk/emc/product/407/smpc.
   Google Scholar
• Cottini M, Asero R. Asthma phenotypes today. Eur Ann Allergy Clin Immunol. 2013;45(1):17–24.
   PubMedGoogle Scholar
• Holgate ST. Genetic and environmental interaction in allergy and asthma. J Allergy Clin Immunol. 1999;104(6):1139–1146.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma [Internet]. Global strategy for asthma management and prevention, 2020 Appendix. [ cited 2020 Apr 10]. Available from: https://ginasthma.org/reports/.
   Google Scholar
• Sumi Y, Hamid Q. Airway remodeling in asthma. Allergol Int. 2007;56(4):341–348.
   PubMedGoogle Scholar
• Gosens R, Gross N. The mode of action of anticholinergics in asthma. Eur Respir J. 2018;52(4):1701247.
   PubMed Web of Science ®Google Scholar
• Proskocil BJ, Sekhon HS, Jia Y, et al. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology. 2004;145(5):2498–2506.
   PubMed Web of Science ®Google Scholar
• Novelli F, Malagrinò L, Dente FL, et al. Efficacy of anticholinergic drugs in asthma. Expert Rev Respir Med. 2012;6(3):309–319.
   PubMed Web of Science ®Google Scholar
• Ohta S, Oda N, Yokoe T, et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy. 2010;40(8):1266–1275.
   PubMed Web of Science ®Google Scholar
• Buels KS, Fryer AD. Muscarinic receptor antagonists: effects on pulmonary function. Handb Exp Pharmacol. 2012;208:317–341.
   PubMedGoogle Scholar
• Bos IS, Gosens R, Zuidhof AB, et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J. 2007;30(4):653–661.
   PubMed Web of Science ®Google Scholar
• Kistemaker LE, Hiemstra PS, Bos IS, et al. Tiotropium attenuates IL-13-induced goblet cell metaplasia of human airway epithelial cells. Thorax. 2015;70(7):668–676.
   PubMed Web of Science ®Google Scholar
• Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva™): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999;64(6–7):457–464.
   PubMed Web of Science ®Google Scholar
• Billington CK, Penn RB, Hall IP. β2 agonists. Handb Exp Pharmacol. 2017;237:23–40.
   PubMedGoogle Scholar
• Lipworth BJ. Antagonism of long-acting beta2-adrenoceptor agonism. Br J Clin Pharmacol. 2002;54(3):231–245.
   PubMed Web of Science ®Google Scholar
• Blais CM, Davis BE, Cockcroft DW, “Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics”. [Respiratory Medicine. 118 (September 2016) 96–101]. Respir Med. 2017;132:268.
   PubMed Web of Science ®Google Scholar
• Anzalone G, Gagliardo R, Bucchieri F, et al. IL-17A induces chromatin remodeling promoting IL-8 release in bronchial epithelial cells: effect of tiotropium. Life Sci. 2016;152:107–116.
   PubMed Web of Science ®Google Scholar
• Toumpanakis D, Loverdos K, Tzouda V, et al. Tiotropium bromide exerts anti-inflammatory effects during resistive breathing, an experimental model of severe airway obstruction. Int J Chron Obstruct Pulmon Dis. 2017;12:2207–2220.
   PubMed Web of Science ®Google Scholar
• Neri T, Scalise V, Passalacqua I, et al. Tiotropium inhibits proinflammatory microparticle generation by human bronchial and endothelial cells. Sci Rep. 2019;9(1):11631.
   PubMedGoogle Scholar
• Wang J, Diao X, Zhu H, et al. Effect of tiotropium bromide on airway inflammation and programmed cell death 5 in a mouse model of ovalbumin-induced allergic asthma. Can Respir J. 2019;2019.
   Web of Science ®Google Scholar
• Bateman E, Rennard S, Barnes P, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther. 2009;22(6):533–542.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26.
   PubMed Web of Science ®Google Scholar
• Peters SP, Jones CA, Haselkorn T, et al. Real-world evaluation of asthma control and treatment (REACT): findings from a national web-based survey. J Allergy Clin Immunol. 2007;119(6):1454–1461.
   PubMed Web of Science ®Google Scholar
• Demoly P, Paggiaro P, Plaza V, et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev. 2009;18(112):105–112.
   PubMedGoogle Scholar
• Global Initiative for Asthma [Internet]. Global strategy for asthma management and prevention, 2020 What’s new in GINA 2020. [ cited 2020 Apr 10]. Available from: https://ginasthma.org/gina-reports/
   Google Scholar
• Federal registrar [Internet]. National Asthma Education and Prevention Program (NAEPP) guidelines 2020 working draft. [ cited 2020 Feb 21]. Available from: https://www.federalregister.gov/documents/2019/12/02/2019-26017/request-for-information-on-update-on-selected-topics-in-asthma-management-2020-a-report-from-the.
   Google Scholar
• National Heart, Lung, and Blood Institute [Internet]. National Asthma Education and Prevention Program (NAEPP) guidelines for the diagnosis and management of asthma (EPR-3). [ cited 2020 Feb 21]. Available from: https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma.
   Google Scholar
• Albertson TE, Chenoweth JA, Adams JY, et al. Muscarinic antagonists in early stage clinical development for the treatment of asthma. Expert Opin Investig Drugs. 2017;26(1):35–49.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3(5):367–376.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Disse B, Schröder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128(2):308–314.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128(2):315–322.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Kirsten AM, Dusser D, et al. Pharmacodynamics and pharmacokinetics following once-daily and twice-daily dosing of tiotropium Respimat® in asthma using standardized sample-contamination avoidance. J Aerosol Med Pulm Drug Deliv. 2016;29(5):406–415.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Moroni-Zentgraf P, Ablinger O, et al. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respir Res. 2014;15:61.
   Web of Science ®Google Scholar
• Timmer W, Moroni-Zentgraf P, Cornelissen P, et al. Once-daily tiotropium Respimat® 5 µg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. Respir Med. 2015;109(3):329–338.
   PubMed Web of Science ®Google Scholar
• Paggiaro P, Halpin DM, Buhl R, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2016;4(1):104–113.e2.
   PubMed Web of Science ®Google Scholar
• Ohta K, Ichinose M, Tohda Y, et al. Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study. PLoS One. 2015;10(4):e0124109.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Engel M, Laki I, et al. Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma. J Allergy Clin Immunol Pract. 2018;6(6):2160–2162.e9.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Engel M, Moroni-Zentgraf P, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. Respir Med. 2014;108(9):1268–1276.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, et al. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. Respir Res. 2015;16(1):20.
   PubMedGoogle Scholar
• Hamelmann E, Bateman ED, Vogelberg C, et al. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol. 2016;138(2):441–450.e8.
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Bernstein JA, Vandewalker M, et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017;49(1).
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Murphy K, Harper T 3rd, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017;140(5):1277–1287.
   PubMed Web of Science ®Google Scholar
• Vrijlandt E, El Azzi G, Vandewalker M, et al. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2018;6(2):127–137.
   PubMed Web of Science ®Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715–1726.
   PubMed Web of Science ®Google Scholar
• Spiriva® Respimat® prescribing information [ cited 2019 Dec 31]. Available from https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva%20Respimat/spirivarespimat.pdf
   Google Scholar
• Rodrigo GJ, Castro-Rodríguez JA. Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2015;115(3):211–216.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: a systematic review. Pediatr Allergy Immunol. 2017;28(6):573–578.
   PubMed Web of Science ®Google Scholar
• Vandewalker ML, Hamelmann E, Engel M, et al. Once-daily tiotropium Respimat® add-on therapy has a safety profile comparable with placebo in children and adolescents. J Allergy Clin Immunol. 2017;139(2):AB94.
   Web of Science ®Google Scholar
• Hamelmann E, Szefler SJ. Efficacy and safety of tiotropium in children and adolescents. Drugs. 2018;78(3):327–338.
   PubMed Web of Science ®Google Scholar
• Abadoglu O, Berk S. Tiotropium may improve asthma symptoms and lung function in asthmatic patients with irreversible airway obstruction: the real-life data. Clin Respir J. 2016;10(4):421–427.
   PubMed Web of Science ®Google Scholar
• Price D, Kaplan A, Jones R, et al. Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide. J Asthma Allergy. 2015;8:1–13.
   PubMed Web of Science ®Google Scholar
• Dusser D, Ducharme FM. Safety of tiotropium in patients with asthma. Ther Adv Respir Dis. 2019;13:1753466618824010.
   Web of Science ®Google Scholar
• Kerstjens HA, O’Byrne PM. Tiotropium for the treatment of asthma: a drug safety evaluation. Expert Opin Drug Saf. 2016;15(8):1115–1124.
   PubMed Web of Science ®Google Scholar
• Gregory MD, Mersfelder TL, Jamieson T. Accidental overdose of tiotropium in a patient with atrial fibrillation. Ann Pharmacother. 2010;44(2):391–393.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Leimer I, Metzdorf N, et al. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial. Respir Res. 2015;16(1):65.
   PubMed Web of Science ®Google Scholar
• Hohlfeld JM, Furtwaengler A, Könen-Bergmann M, et al. Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials. Int J Clin Pract. 2015;69(1):72–80.
   PubMed Web of Science ®Google Scholar
• Dahl R, Engel M, Dusser D, et al. Safety and tolerability of once-daily tiotropium Respimat® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis. Respir Med. 2016;118:102–111.
   PubMed Web of Science ®Google Scholar
• Zafari Z, Sadatsafavi M, Mark FitzGerald J, et al. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Resour Alloc. 2018;16:3.
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–225.
   PubMed Web of Science ®Google Scholar
• Willson J, Bateman ED, Pavord I, et al. Erratum to: cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists. Appl Health Econ Health Policy. 2016;14(1):119–125.
   PubMed Web of Science ®Google Scholar
• Willson J, Bateman ED, Pavord I, et al. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists. Appl Health Econ Health Policy. 2014;12(4):447–459.
   PubMedGoogle Scholar
• Echave M, Ojanguren ME, Elías I, et al. Cost-effectiveness of tiotropium in the treatment of patients with asthma. Value Health. 2015;18(7):A501–A502.
   Google Scholar
• Silva Miguel L, Manaças M, Pinheiro B. Economic evaluation of tiotropium for severe persistent asthma in Portugal. Value Health. 2015;18(7):A502.
   Web of Science ®Google Scholar
• Pawlik M, Walczak J, Pieniazek I. Economic evaluation of tiotropium administrated through the Respimat inhaler as add-on therapy in patients with uncontrolled severe asthma in Poland. Value Health. 2015;18(7):A502.
   Web of Science ®Google Scholar
• Silva D, Jacinto T. Inhaled β2-agonists in asthma management: an evolving story. Breathe (Sheff). 2016;12(4):375–377.
   PubMedGoogle Scholar
• Kwda A, Gldc P, Baui B, et al. Effect of long term inhaled corticosteroid therapy on adrenal suppression, growth and bone health in children with asthma. BMC Pediatr. 2019;19(1):411.
   PubMed Web of Science ®Google Scholar
• Hossny E, Rosario N, Lee BW, et al. The use of inhaled corticosteroids in pediatric asthma: update. World Allergy Organ J. 2016;9:26.
   PubMed Web of Science ®Google Scholar
• Smith RW, Downey K, Gordon M, et al. Prevalence of hypothalamic-pituitary-adrenal axis suppression in children treated for asthma with inhaled corticosteroid. Paediatr Child Health. 2012;17(5):e34–e39.
   PubMed Web of Science ®Google Scholar
• Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax. 2005;60(9):730–734.
   PubMed Web of Science ®Google Scholar
• Buhl R, FitzGerald JM, Busse WW. Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β(2)-agonists for adults with asthma. Respir Med. 2018;143:82–90.
   PubMed Web of Science ®Google Scholar
• Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.
   PubMedGoogle Scholar
• Volmer T, Effenberger T, Trautner C, et al. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4).
   PubMed Web of Science ®Google Scholar
• Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ. 2003;326(7390):621.
   PubMedGoogle Scholar
• Kaplan A, Fitzgerald JM, El Azzi G, et al. Tiotropium provides greater improvements in FEV1 than leukotriene receptor antagonists as add-on to ICS in adults with asthma. A systematic review. Eur Respir J. 2018;52(suppl 62):PA1033.
   Google Scholar
• Vogelberg C, Goldstein S, Graham L, et al. A comparison of tiotropium, long-acting β2-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma. Respir Res. 2020;21(1):19.
   PubMed Web of Science ®Google Scholar
• Darveaux J, Busse WW. Biologics in asthma–the next step toward personalized treatment. J Allergy Clin Immunol Pract. 2015;32:152–160.
   PubMed Web of Science ®Google Scholar
• Casale TB, Bateman ED, Vandewalker M, et al. Tiotropium Respimat add-on is efficacious in symptomatic asthma, independent of T2 phenotype. J Allergy Clin Immunol Pract. 2018;6(3):923–935.e9.
   PubMed Web of Science ®Google Scholar
• Park HW, Yang MS, Park CS, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy. 2009;64(5):778–783.
   PubMed Web of Science ®Google Scholar
• Price D, Bjermer L, Bergin DA, et al. Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma Allergy. 2017;10:209–223.
   PubMed Web of Science ®Google Scholar
• Hochrainer D, Hölz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat soft mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273–282.
   PubMedGoogle Scholar
• Wachtel H, Kattenbeck S, Dunne S, et al. The Respimat® development story: patient-centered innovation. Pulm Ther. 2017;3(1):19–30.
   Google Scholar
• Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–1417.
   PubMed Web of Science ®Google Scholar